Certolizumab pegol in axial spondyloarthritis. (December 2013)

• Record Type: Journal Article
• Authors: Song, In-Ho; Rudwaleit, Martin
• Is Part Of: Expert review of clinical immunology. Volume 9:Number 12(2013)
• Page Start: 1161
• Page End: 1172
• Publication Date: 2013-12
• Subjects: ankylosing spondylitis -- axial spondyloarthritis -- TNF-α inhibitor; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1586/1744666X.2013.858859
• Languages: English
• ISSNs: 1744-666X

Abstract

The axial spondyloarthritis (SpA) classification criteria cover both patients with ankylosing spondylitis and non-radiographic axial SpA. After failure of NSAIDs TNF-α-inhibitors (TNF-blockers) can be given to patients with active axial SpA. Until recently, the TNF-blockers infliximab, adalimumab, etanercept and golimumab are labeled for the treatment of active ankylosing spondylitis while for active nr-axSpA only adalimumab has been approved in Europe. The TNF-blocker certolizumab pegol has recently been evaluated in the RAPID-axSpA trial which is the first placebo-controlled randomized-controlled trial in the entire group of axial SpA. An elevated C-reactive protein and/ or evidence of bone marrow edema on MRI of the sacroiliac joints were required for inclusion in RAPID-axSpA, and patients could have been preexposed to TNF-blockers. The interesting data of this important trial in the context of the emerging therapeutic field of non-radiographic axial SpA therapy is discussed in this review.